SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer.

ABSTRACT:

Importance

Stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy monotherapy (HDR-BT) are options for intermediate-risk prostate cancer. However, no prospective evidence is available to compare these modalities.

Objective

To compare the biochemical failure (BCF), late patient-reported quality of life (PR-QoL), and acute and late adverse events (AEs) associated with SBRT and HDR-BT using prospective data.

Data sources

This was an individual patient data post hoc pooled analysis of 5 prospective trials with recruitment from 2010 to 2018. Statistical analyses were performed in September 2024.

Study selection

This was a post hoc analysis of these 5 sprospective trials. Eligibility criteria comprised men with intermediate-risk prostate cancer underg

SUBMITTER: Udovicich C 

PROVIDER: S-EPMC12936880 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature